Cargando…

Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer

BACKGROUND: Adjuvant gemcitabine for pancreatic cancer has limited efficacy in the clinical setting. Impaired drug metabolism is associated with treatment resistance. We aimed to evaluate the chemosensitising effect of interferon-beta (IFN-β). METHODS: BxPC-3, CFPAC-1, and Panc-1 cells were pre-trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blaauboer, Amber, Booy, Stephanie, van Koetsveld, Peter M., Karels, Bas, Dogan, Fadime, van Zwienen, Suzanne, van Eijck, Casper H. J., Hofland, Leo J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513525/ https://www.ncbi.nlm.nih.gov/pubmed/32967656 http://dx.doi.org/10.1186/s12885-020-07420-0

Ejemplares similares

The Class I HDAC Inhibitor Valproic Acid Strongly Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Immune System Activation
por: Blaauboer, Amber, et al.
Publicado: (2022)

Influence of type-I Interferon receptor expression level on the response to type-I Interferons in human pancreatic cancer cells
por: Booy, Stephanie, et al.
Publicado: (2014)

Reciprocal Interactions between Fibroblast and Pancreatic Neuroendocrine Tumor Cells: Putative Impact of the Tumor Microenvironment
por: Cuny, Thomas, et al.
Publicado: (2022)

Comparing the Effect of Multiple Histone Deacetylase Inhibitors on SSTR2 Expression and [(111)In]In-DOTATATE Uptake in NET Cells
por: Klomp, Maria J., et al.
Publicado: (2021)

Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells
por: Veenstra, Marije J., et al.
Publicado: (2016)

Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors
por: Vandamme, Timon, et al.
Publicado: (2016)

Effect of epigenetic treatment on SST(2) expression in neuroendocrine tumour patients
por: Refardt, Julie, et al.
Publicado: (2022)

Evaluation of Spheroid 3D Culture Methods to Study a Pancreatic Neuroendocrine Neoplasm Cell Line
por: Bresciani, Giulia, et al.
Publicado: (2019)

The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures
por: van Koetsveld, Peter M, et al.
Publicado: (2019)

Modifying Effects of Glucose and Insulin/Insulin-Like Growth Factors on Colon Cancer Cells
por: Berk, Şeyda, et al.
Publicado: (2021)

Epigenetic regulation of SST(2) expression in small intestinal neuroendocrine tumors
por: Klomp, Maria J., et al.
Publicado: (2023)

The Role of the IGF2 Methylation Score in Diagnosing Adrenocortical Tumors with Unclear Malignant Potential—Feasibility of Formalin-Fixed Paraffin-Embedded Tissue
por: Steenaard, Rebecca V., et al.
Publicado: (2023)

Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour
por: da Silva, Tiago Nunes, et al.
Publicado: (2018)

Effects of Ketoconazole on ACTH-Producing and Non-ACTH-Producing Neuroendocrine Tumor Cells
por: Herrera-Martínez, Aura D., et al.
Publicado: (2019)

Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
por: Janssen, Quisette P., et al.
Publicado: (2020)

The Effect of VPA Treatment on Radiolabeled DOTATATE Uptake: Differences Observed In Vitro and In Vivo
por: Klomp, Maria J., et al.
Publicado: (2022)

The value of serum amylase and drain fluid amylase to predict postoperative pancreatic fistula after pancreatoduodenectomy: a retrospective cohort study
por: van Dongen, Jelle C., et al.
Publicado: (2021)

FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study
por: Suker, Mustafa, et al.
Publicado: (2018)

ACTH-independent macronodular adrenocortical hyperplasia reveals prevalent aberrant in vivo and in vitro responses to hormonal stimuli and coupling of arginine-vasopressin type 1a receptor to 11β-hydroxylase
por: Hofland, Johannes, et al.
Publicado: (2013)

Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data
por: Giovinazzo, Francesco, et al.
Publicado: (2020)

Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients
por: van der Sijde, Fleur, et al.
Publicado: (2019)

Circulating DNA and Micro-RNA in Patients with Pancreatic Cancer
por: Vietsch, Eveline E, et al.
Publicado: (2015)

Induction therapy with (177)Lu-DOTATATE procures long-term survival in locally advanced or oligometastatic pancreatic neuroendocrine neoplasm patients
por: Minczeles, Noémie S., et al.
Publicado: (2022)

Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
por: de Jong, Evelien J. M., et al.
Publicado: (2021)

Pancreatic Duct Obstruction in a Middle-Aged Woman: A Case Report
por: Suker, Mustafa, et al.
Publicado: (2017)

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
por: Demols, A, et al.
Publicado: (2006)

The yield of chest computed tomography in patients with locally advanced pancreatic cancer
por: Suker, Mustafa, et al.
Publicado: (2020)

Analyzing Flow Cytometry or Targeted Gene Expression Data Influences Clinical Discoveries—Profiling Blood Samples of Pancreatic Ductal Adenocarcinoma Patients
por: de Koning, Willem, et al.
Publicado: (2023)

The Daily Practice of Pancreatic Enzyme Replacement Therapy After Pancreatic Surgery: a Northern European Survey: Enzyme Replacement After Surgery
por: Sikkens, Edmée C. M., et al.
Publicado: (2012)

Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma
por: Farshadi, Elham Aida, et al.
Publicado: (2021)

Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma
por: Buijs, Pascal, et al.
Publicado: (2015)

The need for a new toxicity testing and risk analysis paradigm to implement REACH or any other large scale testing initiative
por: Blaauboer, Bas J., et al.
Publicado: (2007)

Cyclopentenyl cytosine increases gemcitabine radiosensitisation in human pancreatic cancer cells
por: van Bree, C, et al.
Publicado: (2008)

Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
por: Janssen, Q. P., et al.
Publicado: (2021)

Oxidized and Aggregated Recombinant Human Interferon Beta is Immunogenic in Human Interferon Beta Transgenic Mice
por: van Beers, Miranda M. C., et al.
Publicado: (2011)

Current evidence of nutritional therapy in pancreatoduodenectomy: Systematic review of randomized controlled trials
por: Takagi, Kosei, et al.
Publicado: (2019)

Cytopathological Analysis of Cyst Fluid Enhances Diagnostic Accuracy of Mucinous Pancreatic Cystic Neoplasms
por: Utomo, Wesley K., et al.
Publicado: (2015)

IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer
por: De Martino, Maria Cristina, et al.
Publicado: (2019)

Quality of life of locally advanced pancreatic cancer patients after FOLFIRINOX treatment
por: van der Sijde, Fleur, et al.
Publicado: (2021)

Gold Nanoparticles sensitize pancreatic cancer cells to gemcitabine
por: Huai, Yanyan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qpijdc7bjj31sb0b5gfgrfs46h